RATIONALE: Previous studies investigating comorbidity impact on biologic effectiveness have been relatively small, of short duration, and have not compared biologic classes. OBJECTIVES: To determine the association between T2-related comorbidities and biologic effectiveness in adults with severe asthma (SA). METHODS: This cohort study used International Severe Asthma Registry data (n=21 countries, 2017-2022) to quantify pre- to post-biologic change for four outcomes (annual asthma exacerbation rate, % predicted FEV1 (ppFEV1), asthma control, and long-term oral corticosteroid daily dose [LTOCS]) in patients with/without allergic rhinitis (AR), chronic rhinosinusitis +/- nasal polyps (CRS+/-NP), NP, or eczema/atopic dermatitis (AD). MAIN RESU...
OBJECTIVE To determine the prevalence of systemic corticosteroid-induced morbidity in severe asth...
Background: Greater precision in asthma exacerbation risk prediction may improve outcomes. We sought...
T2-associated diseases are a group of heterogeneous immune-mediated diseases such as bronchial asthm...
Background: Although prevalence of co-existing type 2 inflammatory diseases (cT2) in asthma patients...
BACKGROUND: Effectiveness of biologics has neither been established in patients with high oral corti...
David Price,1,2 Andrew Menzies-Gow,3 Claus Bachert,4 Giorgio Walter Canonica,5 Janwillem Kocks,1 Asi...
Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not i...
Background: Nasal polyps (NPs) are a common comorbidity of asthma. Differences in disease endotype a...
BACKGROUND: There is little agreement on clinically useful criteria for identifying real-world respo...
Purpose of review Severe asthma is a heterogeneous syndrome that can be classified into distinct phe...
BACKGROUND: We aimed to evaluate the effectiveness of different antibody therapies on nasal polyp sy...
Background: It is unclear whether asthma and asthma medications increase or decrease the risk of sev...
OBJECTIVE To determine the prevalence of systemic corticosteroid-induced morbidity in severe asth...
Background: Greater precision in asthma exacerbation risk prediction may improve outcomes. We sought...
T2-associated diseases are a group of heterogeneous immune-mediated diseases such as bronchial asthm...
Background: Although prevalence of co-existing type 2 inflammatory diseases (cT2) in asthma patients...
BACKGROUND: Effectiveness of biologics has neither been established in patients with high oral corti...
David Price,1,2 Andrew Menzies-Gow,3 Claus Bachert,4 Giorgio Walter Canonica,5 Janwillem Kocks,1 Asi...
Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not i...
Background: Nasal polyps (NPs) are a common comorbidity of asthma. Differences in disease endotype a...
BACKGROUND: There is little agreement on clinically useful criteria for identifying real-world respo...
Purpose of review Severe asthma is a heterogeneous syndrome that can be classified into distinct phe...
BACKGROUND: We aimed to evaluate the effectiveness of different antibody therapies on nasal polyp sy...
Background: It is unclear whether asthma and asthma medications increase or decrease the risk of sev...
OBJECTIVE To determine the prevalence of systemic corticosteroid-induced morbidity in severe asth...
Background: Greater precision in asthma exacerbation risk prediction may improve outcomes. We sought...
T2-associated diseases are a group of heterogeneous immune-mediated diseases such as bronchial asthm...